Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06804668 · ClinicalTrials.gov registry record · NA
Safety and Feasibility of Tele-supervised Home-based Transcranial Direct Current Stimulation in Parkinson's Disease
A NA study of Parkinson Disease, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT06804668: Recruiting NA study of Parkinson Disease, sponsored by Brigham and Women's Hospital.
NCT06804668 is a NA study of Parkinson Disease that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 6 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06804668, a NA study of Parkinson Disease, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn whether home-based transcranial direct current stimulation (tDCS) is safe and practical for people aged 40 to 70 years with Parkinson's Disease. The study aims to find out if participants can use the tDCS device at home without serious side effects and whether it is easy for them to use on their own. Participants will first attend an in-person visit to learn how to use the tDCS device. They will then use the device at home once a day for 20 minutes over seven consecutive days. Video calls on days 2 and 3 will provide support and supervision. After each session, participants will complete brief online questionnaires about any side effects and how easy the device was to use. The study will also check if using tDCS at home improves motor symptoms in Parkinson's Disease by using a standard movement assessment.
Primary Outcome
Measures the total number of days each participant successfully completes tDCS sessions at home, aiming for seven consecutive days. Method: Daily online logs.
Conditions Studied
Interventions
- DEVICE tDCS
Study Locations (1)
Massachusetts
- Center for Brain Circuit Therapeutics, Department of Neurology, Brigham & Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2025-02-06 |
| Est. Completion | 2026-09-01 |
| Phase | NA |
What NCT06804668 shows while recruiting
NCT06804668 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which tDCS is the first listed.
NCT06804668 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06804668 about?
NCT06804668 is a clinical study titled "Safety and Feasibility of Tele-supervised Home-based Transcranial Direct Current Stimulation in Parkinson's Disease". The goal of this clinical trial is to learn whether home-based transcranial direct current stimulation (tDCS) is safe and practical for people aged 40 to 70 years with Parkinson's Disease. The study aims to find out if participants can use the tDCS device at home without serious side effects and whe...
What is the current status of trial NCT06804668?
This trial is currently recruiting. It is a NA study. The enrollment target is 6 participants. The study started on 2025-02-06. Estimated completion is 2026-09-01.
What conditions does trial NCT06804668 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT06804668?
The interventions under investigation include: tDCS (DEVICE).
Who is sponsoring clinical trial NCT06804668?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06804668 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06804668's enrollment target sits among peer trials
6 291st of 297 higher than 7 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Neurophysiology of Reward Signaling in Parkinson's Disease
RECRUITING · NA
-
Balance Tele-Rehab in Parkinson's Disease Parkinson's Disease
RECRUITING · NA
-
Rock Steady Boxing: A Community Based In Person Class
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI